Editas Medicine Company Insiders
| EDIT Stock | USD 5.35 0.11 2.01% |
Editas Medicine's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Editas Medicine suggests that vertually all insiders are panicking. Editas Medicine employs about 265 people. The company is managed by 35 executives with a total tenure of roughly 141 years, averaging almost 4.0 years of service per executive, having 7.57 employees per reported executive.
| Katrine Bosley CEO President CEO, Director |
| James Mullen Chairman Chairman of the Board |
Editas Medicine's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-03-05 | Gilmore Neil O'neill | Disposed 77824 @ 9.42 | View | ||
| 2024-03-04 | Baisong Mei | Disposed 20327 @ 9.42 | View | ||
| 2023-12-05 | Bruce Eaton | Disposed 103 @ 10.9 | View | ||
| 2023-11-07 | Bruce Eaton | Disposed 139 @ 8.4 | View | ||
| 2023-09-06 | Bruce Eaton | Disposed 103 @ 8.82 | View | ||
| 2023-08-11 | Bruce Eaton | Disposed 702 @ 8.59 | View | ||
| 2023-08-08 | Bruce Eaton | Disposed 141 @ 8.39 | View | ||
| 2023-07-19 | Baisong Mei | Disposed 4317 @ 8.8 | View | ||
| 2023-06-05 | Gilmore Neil O'neill | Disposed 6486 @ 9.5 | View | ||
| 2023-05-11 | Bruce Eaton | Disposed 668 @ 9.87 | View | ||
| 2023-05-09 | Bruce Eaton | Disposed 135 @ 9.51 | View |
Monitoring Editas Medicine's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Editas |
Editas Medicine's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Editas Medicine's future performance. Based on our forecasts, it is anticipated that Editas will maintain a workforce of slightly above 270 employees by May 2024.Editas Medicine's latest congressional trading
Congressional trading in companies like Editas Medicine, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Editas Medicine by those in governmental positions are based on the same information available to the general public.
| 2023-04-10 | Representative Daniel Goldman | Acquired Under $15K | Verify | ||
| 2021-04-14 | Representative Donald S. Beyer, Jr. | Acquired Under $15K | Verify | ||
| 2019-06-04 | Representative Donna Shalala | Disposed Under $15K | Verify | ||
| 2019-02-04 | Senator James M Inhofe | Acquired $15K to $50K | Verify | ||
| 2019-02-04 | Senator James M. Inhofe | Acquired $15K to $50K | Verify |
Editas Medicine Management Team Effectiveness
The company has return on total asset (ROA) of (0.2087) % which means that it has lost $0.2087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4317) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. Non Current Liabilities Total is likely to gain to about 115.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.Common Stock Shares Outstanding is likely to drop to about 49.3 M in 2024. Net Loss is likely to gain to about (188.5 M) in 2024
Editas Medicine Workforce Comparison
Editas Medicine is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 9,459. Editas Medicine holds roughly 265 in number of employees claiming about 2.8% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.96) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.4) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.4. Editas Medicine Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Editas Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Editas Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Editas Medicine insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 7.0 | 14 | 2 | 1,191,361 | 98,151 |
| 2023-09-01 | 0.5 | 2 | 4 | 180,667 | 5,263 |
| 2023-06-01 | 2.0 | 10 | 5 | 458,700 | 8,343 |
| 2023-03-01 | 1.1429 | 8 | 7 | 464,700 | 12,767 |
| 2022-09-01 | 0.3333 | 1 | 3 | 58,372 | 586.00 |
| 2022-06-01 | 3.2 | 16 | 5 | 1,617,187 | 9,350 |
| 2022-03-01 | 1.2 | 6 | 5 | 484,511 | 21,468 |
| 2021-12-01 | 1.5 | 6 | 4 | 82,479 | 15,660 |
| 2021-09-01 | 0.3333 | 3 | 9 | 52,714 | 226,177 |
| 2021-06-01 | 3.0 | 9 | 3 | 316,598 | 5,000 |
| 2021-03-01 | 2.5 | 5 | 2 | 269,937 | 2,830 |
| 2020-12-01 | 0.5 | 6 | 12 | 203,076 | 83,228 |
| 2020-09-01 | 0.2857 | 2 | 7 | 20,000 | 45,214 |
| 2020-06-01 | 5.0 | 5 | 1 | 57,690 | 151.00 |
| 2020-03-01 | 1.75 | 7 | 4 | 348,501 | 24,148 |
| 2019-12-01 | 2.0 | 2 | 1 | 175,000 | 0.00 |
| 2019-09-01 | 5.0 | 5 | 1 | 786,566 | 5,193 |
| 2019-03-01 | 1.0 | 15 | 15 | 216,903 | 65,790 |
| 2018-12-01 | 0.4286 | 12 | 28 | 66,644 | 111,852 |
| 2018-09-01 | 0.4074 | 11 | 27 | 46,000 | 132,666 |
| 2018-06-01 | 0.52 | 13 | 25 | 95,314 | 488,453 |
| 2018-03-01 | 0.3438 | 11 | 32 | 587,652 | 180,133 |
| 2017-12-01 | 0.1765 | 3 | 17 | 14,649 | 74,297 |
| 2017-09-01 | 0.2 | 1 | 5 | 1,686 | 33,332 |
| 2017-06-01 | 4.5 | 9 | 2 | 131,304 | 1,000,000 |
| 2017-03-01 | 0.7778 | 7 | 9 | 474,500 | 50,000 |
| 2016-12-01 | 0.0526 | 1 | 19 | 225,000 | 718,058 |
| 2016-09-01 | 0.3636 | 4 | 11 | 250,561 | 3,308,161 |
| 2016-03-01 | 0.434 | 23 | 53 | 32,279,313 | 78,507,074 |
Editas Medicine Notable Stakeholders
An Editas Medicine stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Editas Medicine often face trade-offs trying to please all of them. Editas Medicine's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Editas Medicine's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
About Editas Medicine Management Performance
The success or failure of an entity such as Editas Medicine often depends on how effective the management is. Editas Medicine management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Editas management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Editas management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (0.44) | (0.46) |
The data published in Editas Medicine's official financial statements usually reflect Editas Medicine's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Editas Medicine. For example, before you start analyzing numbers published by Editas accountants, it's critical to develop an understanding of what Editas Medicine's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Editas Medicine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Editas Medicine's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Editas Medicine's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Editas Medicine. Please utilize our Beneish M Score to check the likelihood of Editas Medicine's management manipulating its earnings.
Editas Medicine Workforce Analysis
Traditionally, organizations such as Editas Medicine use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Editas Medicine within its industry.Editas Medicine Manpower Efficiency
Return on Editas Medicine Manpower
| Revenue Per Employee | 294.8K | |
| Revenue Per Executive | 2.2M | |
| Net Loss Per Employee | 578.2K | |
| Net Loss Per Executive | 4.4M | |
| Working Capital Per Employee | 1M | |
| Working Capital Per Executive | 7.9M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.